Adicet Bio (ACET) Stock Forecast, Price Target & Predictions
ACET Stock Forecast
Adicet Bio stock forecast is as follows: an average price target of $32.50 (represents a 3257.78% upside from ACET’s last price of $0.97) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.
ACET Price Target
The average price target for Adicet Bio (ACET) is $32.50 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $38.00 to $27.00. This represents a potential 3257.78% upside from ACET's last price of $0.97.
ACET Analyst Ratings
According to 7 Wall Street analysts, Adicet Bio's rating consensus is 'Buy'. The analyst rating breakdown for ACET stock is 0 'Strong Buy' (0.00%), 4 'Buy' (57.14%), 3 'Hold' (42.86%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Adicet Bio Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Dec 12, 2022 | - | H.C. Wainwright | $38.00 | $17.27 | 120.03% | 3826.03% |
| Mar 04, 2022 | Kelly Shi | Jefferies | $27.00 | $12.56 | 114.97% | 2689.54% |
The latest Adicet Bio stock forecast, released on Dec 12, 2022 by H.C. Wainwright company, set a price target of $38.00, which represents a 120.03% increase from the stock price at the time of the forecast ($17.27), and a 3826.03% increase from ACET last price ($0.97).
Adicet Bio Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $0.97 | $0.97 | $0.97 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Adicet Bio stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Adicet Bio's last price of $0.97. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 17, 2024 | H.C. Wainwright | Neutral | Neutral | Hold |
| Sep 30, 2024 | Guggenheim | - | Buy | Upgrade |
| Sep 20, 2024 | H.C. Wainwright | Neutral | Neutral | Hold |
| Sep 11, 2024 | Piper Sandler | - | Neutral | Downgrade |
| Sep 11, 2024 | Canaccord Genuity | Buy | Buy | Hold |
| Sep 11, 2024 | H.C. Wainwright | - | Neutral | Downgrade |
| Nov 09, 2023 | Wedbush | Outperform | Outperform | Hold |
| Jun 27, 2023 | JMP Securities | - | Market Perform | Downgrade |
| Mar 04, 2022 | Jefferies | - | Buy | Initialise |
Adicet Bio's last stock rating was published by H.C. Wainwright on Oct 17, 2024. The company gave ACET a "Neutral" rating, the same as its previous rate.
Adicet Bio Financial Forecast
Adicet Bio Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Mar 20 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | $-24.99M | - | - | $24.99M | $6.02M | $3.43M | $4.81M | $-3.98M | $2.00M | $-7.05M |
| Avg Forecast | - | - | - | - | $625.00K | $625.00K | $625.00K | $625.00K | $1.11M | $12.67M | $4.42M | $13.00M | $333.33K | $1.11M | $14.39M | $4.16M | $2.69M | $2.00M | $1.17M | $2.59M | $-5.17M |
| High Forecast | - | - | - | - | $625.00K | $627.50K | $625.00K | $625.00K | $1.11M | $12.67M | $4.42M | $13.00M | $333.33K | $1.11M | $14.39M | $4.16M | $2.69M | $2.00M | $1.17M | $3.10M | $-4.14M |
| Low Forecast | - | - | - | - | $625.00K | $622.50K | $625.00K | $625.00K | $1.11M | $12.67M | $4.42M | $13.00M | $333.33K | $1.11M | $14.39M | $4.16M | $2.69M | $2.00M | $1.17M | $2.07M | $-6.21M |
| # Analysts | - | - | - | - | 1 | 8 | 5 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 7 | 7 | 7 | 7 | 15 | 18 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | -1.92% | - | - | 1.74% | 1.45% | 1.28% | 2.41% | -3.41% | 0.77% | 1.36% |
Adicet Bio's average Quarter revenue forecast for Mar 23 based on 2 analysts is $4.42M, with a low forecast of $4.42M, and a high forecast of $4.42M. ACET's average Quarter revenue forecast represents a -117.70% decrease compared to the company's last Quarter revenue of $-24.99M (Dec 22).
Adicet Bio EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Mar 20 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 8 | 5 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 7 | 7 | 7 | 7 | 15 | 18 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-34.89M | $-30.86M | $-29.85M | $-21.22M | $-22.11M | $5.03M | $-16.15M | $-13.56M | $-10.42M | $-20.99M | $-6.85M | $-14.78M |
| Avg Forecast | - | - | - | - | $-375.00K | $-375.00K | $-375.00K | $-375.00K | $-666.67K | $-7.60M | $-2.65M | $-7.80M | $-200.00K | $-668.57K | $11.47M | $-2.50M | $-1.61M | $-1.20M | $-16.01M | $-8.86M | $-10.85M |
| High Forecast | - | - | - | - | $-375.00K | $-373.50K | $-375.00K | $-375.00K | $-666.63K | $-7.60M | $-2.65M | $-7.80M | $-200.00K | $-668.57K | $13.77M | $-2.50M | $-1.61M | $-1.20M | $-12.81M | $-7.09M | $-8.68M |
| Low Forecast | - | - | - | - | $-375.00K | $-376.50K | $-375.00K | $-375.00K | $-666.70K | $-7.60M | $-2.65M | $-7.80M | $-200.00K | $-668.57K | $9.18M | $-2.50M | $-1.61M | $-1.20M | $-19.21M | $-10.63M | $-13.02M |
| Surprise % | - | - | - | - | - | - | - | - | - | 4.59% | 11.63% | 3.83% | 106.10% | 33.08% | 0.44% | 6.46% | 8.41% | 8.68% | 1.31% | 0.77% | 1.36% |
1 analysts predict ACET's average Quarter EBITDA for Jun 22 to be $-668.57K, with a high of $-668.57K and a low of $-668.57K. This is -113.30% lower than Adicet Bio's previous annual EBITDA (Mar 22) of $5.03M.
Adicet Bio Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Mar 20 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 8 | 5 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 7 | 7 | 7 | 7 | 15 | 18 |
| Net Income | - | - | - | - | - | - | - | - | - | $-32.40M | $-29.63M | $-28.10M | $-21.01M | $-22.37M | $4.62M | $-15.81M | $-14.01M | $-10.85M | $-21.32M | $-4.49M | $-14.78M |
| Avg Forecast | $-30.89M | $-33.92M | $-32.70M | $-31.49M | $-31.91M | $-30.93M | $-33.06M | $-63.29M | $-66.95M | $-41.79M | $-52.35M | $-25.44M | $-48.20M | $-41.24M | $10.62M | $-38.18M | $-38.97M | $-47.26M | $-16.26M | $-5.80M | $-10.85M |
| High Forecast | $-30.89M | $-33.92M | $-32.70M | $-31.49M | $-31.05M | $-30.93M | $-33.06M | $-39.56M | $-66.95M | $-41.79M | $-52.35M | $-25.44M | $-48.20M | $-41.24M | $12.75M | $-38.18M | $-38.97M | $-47.26M | $-13.01M | $-4.64M | $-8.68M |
| Low Forecast | $-30.89M | $-33.92M | $-32.70M | $-31.49M | $-32.77M | $-30.93M | $-33.06M | $-77.35M | $-66.95M | $-41.79M | $-52.35M | $-25.44M | $-48.20M | $-41.24M | $8.50M | $-38.18M | $-38.97M | $-47.26M | $-19.51M | $-6.96M | $-13.02M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.78% | 0.57% | 1.10% | 0.44% | 0.54% | 0.43% | 0.41% | 0.36% | 0.23% | 1.31% | 0.77% | 1.36% |
Adicet Bio's average Quarter net income forecast for Jun 22 is $-41.24M, with a range of $-41.24M to $-41.24M. ACET's average Quarter net income forecast represents a -992.97% decrease compared to the company's last Quarter net income of $4.62M (Mar 22).
Adicet Bio SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Mar 20 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 8 | 5 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 7 | 7 | 7 | 7 | 15 | 18 |
| SG&A | - | - | - | - | - | - | - | - | - | $6.53M | $6.57M | $6.55M | $6.42M | $6.53M | $6.80M | $6.35M | $5.21M | $5.03M | $5.63M | $2.52M | $1.85M |
| Avg Forecast | - | - | - | - | $1.79M | $1.79M | $1.79M | $1.79M | $3.19M | $36.34M | $12.69M | $37.30M | $956.19K | $3.20M | $41.28M | $11.95M | $7.71M | $5.74M | $3.35M | $7.42M | $-14.84M |
| High Forecast | - | - | - | - | $1.79M | $1.80M | $1.79M | $1.79M | $3.19M | $36.34M | $12.69M | $37.30M | $956.19K | $3.20M | $41.28M | $11.95M | $7.71M | $5.74M | $3.35M | $8.90M | $-11.87M |
| Low Forecast | - | - | - | - | $1.79M | $1.79M | $1.79M | $1.79M | $3.19M | $36.34M | $12.69M | $37.30M | $956.19K | $3.20M | $41.28M | $11.95M | $7.71M | $5.74M | $3.35M | $5.93M | $-17.81M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.18% | 0.52% | 0.18% | 6.71% | 2.04% | 0.16% | 0.53% | 0.68% | 0.88% | 1.68% | 0.34% | -0.12% |
Adicet Bio's average Quarter SG&A projection for Sep 23 is $3.19M, based on 2 Wall Street analysts, with a range of $3.19M to $3.19M. The forecast indicates a -51.17% fall compared to ACET last annual SG&A of $6.53M (Jun 23).
Adicet Bio EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Mar 20 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 8 | 5 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 7 | 7 | 7 | 7 | 15 | 18 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.00 | $-0.69 | $-0.67 | $-0.50 | $-0.56 | $0.12 | $-0.47 | $-0.44 | $-0.34 | $-0.82 | $-0.23 | $-0.75 |
| Avg Forecast | $-0.34 | $-0.37 | $-0.36 | $-0.35 | $-0.35 | $-0.34 | $-0.36 | $-0.70 | $-0.74 | $-0.46 | $-0.58 | $-0.28 | $-0.53 | $-0.46 | $-0.18 | $-0.42 | $-0.43 | $-0.52 | $-0.48 | $-2.35 | $-3.76 |
| High Forecast | $-0.34 | $-0.37 | $-0.36 | $-0.35 | $-0.34 | $-0.34 | $-0.36 | $-0.44 | $-0.74 | $-0.46 | $-0.58 | $-0.28 | $-0.53 | $-0.46 | $-0.18 | $-0.42 | $-0.43 | $-0.52 | $-0.48 | $-2.35 | $-3.76 |
| Low Forecast | $-0.34 | $-0.37 | $-0.36 | $-0.35 | $-0.36 | $-0.34 | $-0.36 | $-0.85 | $-0.74 | $-0.46 | $-0.58 | $-0.28 | $-0.53 | $-0.46 | $-0.18 | $-0.42 | $-0.43 | $-0.52 | $-0.48 | $-2.35 | $-3.76 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.00% | 1.20% | 2.39% | 0.94% | 1.23% | -0.66% | 1.12% | 1.02% | 0.65% | 1.71% | 0.10% | 0.20% |
According to 1 Wall Street analysts, Adicet Bio's projected average Quarter EPS for Jun 22 is $-0.46, with a low estimate of $-0.46 and a high estimate of $-0.46. This represents a -479.17% decrease compared to ACET previous annual EPS of $0.12 (Mar 22).
Adicet Bio Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ACET | Adicet Bio | $0.97 | $32.50 | 3250.52% | Buy |
| NKTX | Nkarta | $2.49 | $21.60 | 767.47% | Buy |
| VOR | Vor Biopharma | $0.78 | $6.00 | 669.23% | Buy |
| AVTE | Aerovate Therapeutics | $2.53 | $13.00 | 413.83% | Hold |
| ANEB | Anebulo Pharmaceuticals | $1.53 | $6.00 | 292.16% | Buy |
| ACRV | Acrivon Therapeutics | $6.27 | $21.83 | 248.17% | Buy |
| PLRX | Pliant Therapeutics | $12.32 | $39.71 | 222.32% | Buy |
| FIXX | Q32 Bio | $0.93 | $2.70 | 190.32% | Buy |
| BCYC | Bicycle Therapeutics | $20.46 | $54.40 | 165.88% | Buy |
| STOK | Stoke Therapeutics | $11.88 | $30.60 | 157.58% | Buy |
| CGEM | Cullinan Oncology | $13.45 | $31.50 | 134.20% | Buy |
| IGMS | IGM Biosciences | $9.22 | $20.33 | 120.50% | Buy |
| KROS | Keros Therapeutics | $54.01 | $102.60 | 89.96% | Buy |
| EWTX | Edgewise Therapeutics | $30.79 | $45.00 | 46.15% | Buy |
| AGIO | Agios Pharmaceuticals | $52.89 | $48.00 | -9.25% | Buy |
| AADI | Aadi Bioscience | $2.15 | $1.63 | -24.19% | Hold |